The phase 3 ECZTRA 3 study included 380 patients with atopic dermatitis assigned 2:1 to receive subcutaneous tralokinumab 300mg every two weeks, plus topical corticosteroids as needed or a placebo every two weeks and topical corticosteroids as needed for 16 weeks. The trial took place over two years.
Data showed that those treated with tralokinumab 300mg every other week, in addition to optional topical steroids, experienced improvements in sleep, itch and AD signs and symptoms at week 56.
The president of the Oregon Medical Research Center and dermatologist, Dr Andrew Blauvelt, explained, “The bottom line is that people do well over time with continued use and no new safety signals developed. The results are critical in reassuring both dermatologists and patients that the long-term use of their medication for their chronic disease is safe and effective for up to two years of use.”